Bekkat-Berkani R - Search Results

1

Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.

Borrow R, Taha MK, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R. Borrow R, et al. J Infect. 2020 Dec;81(6):862-872. doi: 10.1016/j.jinf.2020.07.034. Epub 2020 Jul 31. J Infect. 2020. PMID: 32745637 Free article. Review.

2

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data.

Watson PS, Novy P, Bekkat-Berkani R, Strubbe F, Banzhoff A. Watson PS, et al. Expert Rev Vaccines. 2019 Apr;18(4):343-352. doi: 10.1080/14760584.2019.1580579. Epub 2019 Mar 22. Expert Rev Vaccines. 2019. PMID: 30741040 Review.

3

Vaccines against Meningococcal Diseases.

Pizza M, Bekkat-Berkani R, Rappuoli R. Pizza M, et al. Microorganisms. 2020 Oct 3;8(10):1521. doi: 10.3390/microorganisms8101521. Microorganisms. 2020. PMID: 33022961 Free PMC article. Review.

4

Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents.

Biolchi A, Tomei S, Santini L, La Gaetana R, Mori E, Novy P, Rappuoli R, Bekkat-Berkani R, Giuliani MM, Pizza M. Biolchi A, et al. Pediatr Infect Dis J. 2021 Feb 1;40(2):e66-e71. doi: 10.1097/INF.0000000000002957. Pediatr Infect Dis J. 2021. PMID: 33060520

5

Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.

Martinón-Torres F, Banzhoff A, Azzari C, De Wals P, Marlow R, Marshall H, Pizza M, Rappuoli R, Bekkat-Berkani R. Martinón-Torres F, et al. J Infect. 2021 Jul;83(1):17-26. doi: 10.1016/j.jinf.2021.04.031. Epub 2021 Apr 30. J Infect. 2021. PMID: 33933528 Free article. Review.

6

Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.

Martinón-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, Abitbol V. Martinón-Torres F, et al. Pathog Glob Health. 2022 Mar;116(2):85-98. doi: 10.1080/20477724.2021.1972663. Epub 2021 Sep 27. Pathog Glob Health. 2022. PMID: 34569453 Free PMC article. Review.

7

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect.

Ruiz García Y, Sohn WY, Seib KL, Taha MK, Vázquez JA, de Lemos APS, Vadivelu K, Pizza M, Rappuoli R, Bekkat-Berkani R. Ruiz García Y, et al. NPJ Vaccines. 2021 Oct 29;6(1):130. doi: 10.1038/s41541-021-00388-3. NPJ Vaccines. 2021. PMID: 34716336 Free PMC article. Review.

8

Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.

Sohn WY, Tahrat H, Novy P, Bekkat-Berkani R. Sohn WY, et al. Expert Rev Vaccines. 2022 Mar;21(3):325-335. doi: 10.1080/14760584.2022.2021881. Epub 2022 Feb 23. Expert Rev Vaccines. 2022. PMID: 35068299 Review.

9

Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease.

Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, Smith V, Garcia S, Bekkat-Berkani R, Abitbol V. Taha MK, et al. Among authors: bekkat berkani r. Expert Rev Vaccines. 2022 May;21(5):659-674. doi: 10.1080/14760584.2022.2052048. Epub 2022 Mar 29. Expert Rev Vaccines. 2022. PMID: 35271781 Review.

10

Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.

Bekkat-Berkani R, Fragapane E, Preiss S, Rappuoli R, Sohn WY, Soumahoro L, Vadivelu K. Bekkat-Berkani R, et al. J Infect. 2022 Nov;85(5):481-491. doi: 10.1016/j.jinf.2022.09.001. Epub 2022 Sep 7. J Infect. 2022. PMID: 36087745 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page